Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?

Biodesix, Inc. BDSX shares ended the last trading session 10.5% higher at $16.81. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.9% gain over the past four weeks.

Biodesix scored a strong price increase, on investors’ optimism following reports that Canaccord Genuity raised the company’s price target from $22.00 to $27.00, while maintaining a “Buy” rating. In the first quarter of 2026, Biodesix made strong progress across all three of its objectives — driving top-line growth, improving operational efficiency and leverage, and advancing pipeline to support long-term expansion.

This company is expected to post quarterly loss of $0.85 per share in its upcoming report, which represents a year-over-year change of +46.9%. Revenues are expected to be $26.1 million, up 30.4% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Biodesix, the consensus EPS estimate for the quarter has been revised 4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on BDSX going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Biodesix is a member of the Zacks Medical Services industry. One other stock in the same industry, GoodRx Holdings, Inc. GDRX, finished the last trading session 1.9% higher at $2.66. GDRX has returned 3.6% over the past month.

GoodRx's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.08. Compared to the company's year-ago EPS, this represents a change of -11.1%. GoodRx currently boasts a Zacks Rank of #3 (Hold).

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research